Hardman & Co Research
- Land: United Kingdom
Nachricht vom 14.06.2018 | 10:50
Hardman & Co Research: Oxford BioMedica (OXB): Gene-therapy for Parkinson's: clinical progression
Hardman & Co Research
Hardman & Co Research: Gene-therapy for Parkinson's: clinical progression
OXB is a specialist advanced-therapy lentivirus vector biopharma company. It offers vector manufacturing and development services, and also has a proprietary drug pipeline. In addition to LentiVector(R) service contracts, OXB receives royalties on commercial therapies developed by its partners using the LentiVector platform. A partnership deal structure was established with Novartis for KymriahPPPTM in 2017,PP and was followed by a collaboration and licence agreement with Bioverativ Inc in February 2018. The latest deal, on 6 June 2018, is the first involving OXB's proprietary platform: it will advance the Parkinson's disease gene-therapy to the clinic. Please click here for the full report:
Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.
About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.
GBC im Fokus
Aves One AG: kursziel deutlich angehoben
Die Aves One AG ist im Geschäftsjahr 2017 abermals dynamisch gewachsen. Der Umsatz stieg um fast 90 % auf über 53 Mio. EUR an. Der jetzt gemeldete Erwerb von umfangreichen Rail-Assets (VTG/Nacco-Deal) soll zu weiteren Steigerungen beitragen. Wir erwarten weiteres Wachstum von über 40% im laufenden Jahr sowie einen dynamischen Anstieg in den Folgejahren. Das Ziel von 1 Mrd. Assets und Managment könnte bereits 2019 und damit ein Jahr früher erreicht werden. Unsere Analysten sind vom VTG/Nacco-Deal überzeugt und haben das Kursziel deutlich auf 12,10 Euro erhöht (bisher 9,10 Euro).
Der AKTIONÄR News
15. August 17:29 Cancom nach Zahlen: Das raten die Analysten
15. August 16:55 Apple, Banken, Pharma: Diese Aktien hat Warren Buffett nachgekauft
15. August 16:02 Faktor-Trade des Tages: Fraport
15. August 15:45 DAX: Alarmstufe Rot
Half-yearly financial statements 2018
16. August 2018
Original-Research: SMT Scharf AG (von Montega AG): Kaufen
15. August 2018